Barclays initiated coverage on Ligand Pharmaceuticals with an 'Overweight' rating and set a price target of $345, implying a 15.37% upside from its current price. The biopharma company is expanding its royalty portfolio through investments in cancer therapies with AvenCell Therapeutics and the myopia drug Ryjunea. These moves are expected to boost future royalty revenues, supporting Ligand's growth prospects. The stock currently trades around $299 with a market cap near $6 billion.
Ligand Pharmaceuticals was recently rated 'Overweight' by Barclays with a $345 price target suggesting a 15.37% upside. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 25, 2026 18:42 WIB: out of 100 priced US health stocks, 55 rose and 37 fell. Notable movers include INO at USD 1.23 with a 1.65% gain and 100% buy orders, DGX at USD 232.90 down 1.50%, and ABCL at USD 12.82 up 1.34% with 88% buy orders.
Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...
JPMorgan, Raymond James, and Bank of America all raised their price targets for Meta Platforms this week, citing the company's new Muse AI as a key growth driver beyond its traditional advertising business. JPMorgan raised its target to $920, Raymond...
Forge Resources Corp. has appointed Kevin Budd as a Special Advisor, leveraging his 25+ years of global capital markets and corporate development experience. Budd's expertise will support the advancement of Forge's coal project in Colombia and its go...
Four companies linked to America's freight rail network—Union Pacific, CSX, GATX, and Wabtec—offer durable dividend-paying investments due to their entrenched market positions and pricing power. Union Pacific and CSX operate extensive rail networks i...
Between September 21 and 23, Bitwise XRP ETF expanded its XRP holdings by approximately 14.18 million tokens, bringing its total to over 401 million XRP valued at around $614 million. The fund's disclosures do not clarify whether this increase was du...
